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24Background: The inﬂatable penile prosthesis (IPP) is typically the preferred implant for Peyronie’s disease (PD)
and malleable penile prostheses (MPPs) have been discouraged.
Aims: To evaluate the effectiveness and patient satisfaction of the MPP vs IPP in patients with PD.
Methods: Men with PD and erectile dysfunction who elected for penile implant surgery constituted the study
population. Preoperatively, demographic and comorbidity parameters were recorded. Curvature was measured
with a goniometer at maximum rigidity after intracavernosal injection of a vasoactive agent. Postoperatively,
overall satisfaction was measured at 3, 6, 12, and 24 months on 5-point Likert scale from 1 (dissatisﬁed) to 5
(very satisﬁed).
Results: 166 men with a mean age of 59 ± 10 years were analyzed. The mean preoperative curvature in the
entire cohort was 65 (range ¼ 30e130). 94% of patients with MPP had total resolution of their curvature at
the end of the operation, whereas 8 patients (6%) had residual curvature (25e40). In the IPP group 25 of 30
(83.3%) had a straight penis at the end of surgery, whereas 5 of 30 (16.7%) had residual curvature, with the
mean magnitude being 33 in the MPP group and 30 in the IPP group. 86% of all patients had diabetes. There
were no differences between the 2 implant groups in age, hemoglobin A1c, body mass index, or smoking status.
The mean patient satisfaction was 4.42 ± 0.70 (range ¼ 2e5) and there was no difference between the 2 groups.
The mean follow-up period was 23.4 months (range ¼ 6e29 months).
Conclusion: We found that the MPP is as effective as the IPP in curvature correction in patients with PD, with
similar patient satisfaction for the 2 groups. Habous M, Farag M, Tealab A, et al. Malleable Penile Implant Is
an Effective Therapeutic Option in Men With Peyronie’s Disease and Erectile Dysfunction. Sex Med
2018;6:24e29.
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Malleable Implant Is an Option in PD and ED 25INTRODUCTION
Implanting a penile prosthesis is often the best treatment for
patients with severe erectile dysfunction (ED) that does not
respond to pharmacotherapy. Pharmacotherapy often fails in
patients with diabetes, radical prostatectomy, Peyronie’s disease
(PD), and severe penile ﬁbrosis. Penile prosthetic surgery has
high long-term mechanical reliability and patient satisfaction
rates higher than 85%.1 Penile prosthesis implantation is the
standard procedure for patients with PD and concomitant ED
that does not respond to medical treatment.2 20% to 30% of
patients with PD have ED refractory to medical therapy and can
beneﬁt from a combined procedure addressing these 2 condi-
tions.3 Penile implant placement in these patients can treat the 2
problems by providing penile rigidity and the deformity
correction required. Although patients with mild degrees of
curvature can have complete penile straightening by placement of
the prosthesis alone, many patients have residual curvature
requiring intraoperative adjuvant maneuvers, such as modeling
and plaque incision with or without grafting.4,5
Garaffa et al6 reported that of additional straightening pro-
cedures, modeling was more successful in achieving straightening
when performed on an inﬂatable penile prosthesis (IPP; 84%)
than on a malleable penile prosthesis (MPP; 54%). If the cur-
vature persisted after modeling or the curvature was ventral,
straightening was achieved with tunica plications or incision with
or without grafting. In another study, Levine et al7 reported on a
single-center experience with the IPP and straightening maneu-
vers as necessary in 90 men with medication-refractory ED and
PD. Additional intraoperative maneuvers used to straighten the
penis after placement of the prosthesis included manual
modeling, plaque incision, and grafting, if the defect created with
the incision was large enough (2 cm). In their study, IPP
placement allowed reliable and satisfactory coitus for the great
majority of men (91%).
Although all types of penile implants can be used, implanta-
tion of an IPP has been reported to be the most effective and
preferred in those patients based on the published data.8e10 In
certain regions of the world, the MPP is the penile implant of
choice for ED, often because of economic reasons. However, it
has been suggested the MPP is not ideal for patients with PD.10
Our hypothesis was that the MPP would be as effective as the
IPP in the management of patients with ED and PD. Our clinical
experience suggests that the MPP is an effective strategy in the
treatment of patients with combined PD and ED. We compared
the outcome and satisfaction rate in patients with PD and ED
receiving the MPP compared with those receiving the IPP.METHODS
Study Population
From July 2011 through June 2014, men with PD and ED
not responding to medical therapy were counseled regarding
penile implant surgery.Sex Med 2018;6:24e29Patients who had a favorable clinical response with an intra-
cavernosal injection (ICI) and refused ICI as a therapeutic option
for their ED were included in this study. For this analysis, we
included only those who had a favorable clinical response to ICI
so that we could accurately measure the magnitude of curvature
before surgery. Some patients requested penile implantation after
they noticed that they had lost signiﬁcant penile size. Others who
had signiﬁcant deformity did not wish to undergo corrective
surgery (eg, Nesbit) with subsequent risk of ED and losing more
penile size. They wanted to address their problems with 1 ﬁnal
solution. After good counseling and explaining all therapeutic
options, patients who had a favorable clinical response with ICI
but who found ICI unpalatable and refused further treatment
with ICI were chosen for penile implantation. Penile implant
surgery is the treatment of choice in such men in our practice
and this is supported by International Consultation on Sexual
Medicine guidelines.11
Those who opted for this procedure constituted the study
population. The criteria for penile implant surgery in this pop-
ulation included (i) men in a stable relationship, (ii) men with
penile curvature of at least 30, (iii) men with ED refractory to
medical therapy, and (iv) stable penile curvature for at least 9
months. Complete medical and sexual history, physical exami-
nation, and comorbidities were recorded for all patients. Basic
investigational workup included penile duplex ultrasound study
with ICI for all patients. The MMP used was the Genesis
(Coloplast, Minneapolis, MN, USA) and the IPP used was the
Titan OTR (Coloplast). The study was approved by our insti-
tutional ethical board committee.Penile Deformity Assessment
Curvature was measured with a goniometer at maximum
rigidity after ICI using an intracavernosal quadri-mix (prosta-
glandin E1 5 mg, papaverine 15 mg, phentolamine 1 mg, atro-
pine 20 mg per 1 mL of saline). Repeated dosing was
administered to ensure full erection in all patients (mean dose ¼
0.3 mL, range ¼ 0.1e1 mL).Preoperative Counseling for Implant Type
The preoperative discussion focused on the goal of obtaining
“functional straightness” and patients were informed that a re-
sidual curvature no greater than 20 in any direction would not
compromise sexual activity and that a curvature less than 20 was
the goal and further maneuvers would not be used if such a
residual curvature existed. Advantages and disadvantages of the
MPP and IPP were explained thoroughly for all patients.
Choosing the MPP vs the IPP was the patient’s decision. The
surgeon’s role was to explain the advantages and disadvantages of
each type of implant using educational videos. At our center,
most patients choose the MMP, primarily because the patient
pays for this procedure (no insurance coverage). The average cost
of an MMP in our center is US$1,300 and the total cost of
MMP implantation ranges from US$5,500 to US$6,000. In
26 Habous et alcontrast, the cost of a 3-piece IPP is US$5,800 and the total cost
of IPP implantation ranges from US$12,000 to US$13,000.
Some chose the MPP because of fear of mechanical failure of the
IPP and others chose the MMP because of its simplicity of usage.
The main reason for choosing the IPP was the likelihood of
increased girth compared with the MPP. Concealment was of
minor importance in our patient’s decision making. An informed
consent was signed by all patients. This consent form included all
potential complications for the 2 implant types. This consent
included a statement that penile implant surgery is an irreversible
surgery, so if the patient decided to remove the implant, he could
not have erection again with ICI or oral therapy. When asked,
men dissatisﬁed with their MPP were not likely to change their
mind and would not have chosen an IPP. This is multifactorial
but cost was a major consideration.Implant Surgery
This study was conducted at a single center and included
patients operated on by 4 high-volume surgeons (50 implants/
year). The MPP was implanted through the ventral penile
approach in all patients. A 4- to 6-cm midline incision was made
at the ventral proximal penile shaft. Dissection of the Dartos and
Bucks fascia was performed with exposure of the tunica albuginea
and corpus spongiosum. The Genesis is the implant used by our
center, and the size used is according to the measured length and
the diameter used is 1 mm smaller than the largest dilator
inserted.
The IPP was implanted using the standard scrotal or peno-
scrotal approach in all patients. Dilation in these cases used the
Brooks dilators proximally and distally. After insertion of the
cylinders and maximal inﬂation, residual curvature was measured
as outlined earlier. If residual curvature greater than 20
remained, then the technique of modeling popularized by Wil-
son and Delk5 was used. For the IPP it was necessary during
modeling to initially clamp the cylinder input tubes to protect
the pump from backpressure ﬂow. The prosthetic cylinders were
inﬂated to high pressure, the input tube was clamped with
rubber-shod clamps, and the penis was grasped with both hands
and bent over the inﬂated cylinders at the region of maximum
curvature. Bending was maintained for 90 seconds and then
relaxed. For the MPP, if placement of the rods did not
adequately straighten the erection, then the modeling procedure
was used12; we have found this technique much easier to use inTable 1. Patient demographic and comorbidity data
Parameter Entire cohort (N ¼ 166)
Age (y), mean ± SD (range) 59 ± 9.8 (24e81)
HbA1c (%), mean ± SD (range) 8 ± 1.6
BMI (kg/m2), mean ± SD (range) 30 ± 5
Preoperative curvature (), mean (range) 65 (30e130)
BMI ¼ body mass index; HbA1c ¼ hemoglobin A1c; IPP ¼ inﬂatable penile pro
*IPP vs MPP group.our practice The remaining patients whose modeling failed
required additional procedures for residual curvatures, such as
plaque incision or excision. At least 1 relaxing transverse incision
(H-shape) was made in the plaque using electrocautery. Incisions
were made carefully over the existing prosthesis and were limited
to the tunica, preserving the underlying cavernosal tissue. In
some patients, plaque excision was required to accomplish
complete straightening. To access the plaque for patients
requiring plaque incision or excision, the neurovascular bundle
was routinely elevated. The neurovascular bundle was dissected
and mobilized when needed according to standard surgical
techniques. The same was done for the corpus spongiosum. After
these maneuvers, reassessment of corporal length was conducted
to optimize implant length. In some patients, plaque excision was
needed and this was performed by extending the corporotomy so
that the plaque excision was done under direct vision. The
cutting current in electrocautery with the aid of toothed forceps
was used to dissect the scarred tissue (plaques) from the wall of
the tunica albuginea. Reassessment of corporal length after these
maneuvers was done as described earlier, and any extra cylinder
length was added as needed using rear-tip extenders.Questionnaire
The Sexual Health Inventory for Men (SHIM) questionnaire
was completed as part of the preoperative evaluation of patients
presenting to our clinic complaining of ED. Postoperatively,
overall satisfaction was measured at 3, 6, 12, and 24 months on a
5-point Likert scale (1 ¼ dissatisﬁed, 2 ¼ not satisﬁed, 3 ¼
moderately satisﬁed, 4 ¼ satisﬁed, 5 ¼ very satisﬁed).Statistical Analysis
Descriptive statistics are reported. Statistical analysis was done
using IBM SPSS Statistics (IBM Corporation, Armonk, NY,
USA). Simple independent measures t-tests (2-tailed t-test) were
used for satisfaction and SHIM scores, and c2 tests were used for
group comparisons. A P value less than .05 was considered
statistically signiﬁcant.RESULTS
Patient Population
166 men were included. Patient demographic and comor-
bidity data are presented in Table 1. 82% received an MPP andMPP group (n ¼ 136) IPP group (n ¼ 30) P value*
58.7 ± 9.7 (24e81) 59.1 ± 10.0 (29e75) .75
8.1 ± 1.5 (4.9e12.0) 7.5 ± 1.6 (5.3e10.7) .03
30.2 ± 4.7 (20e48) 30.7 ± 4.8 (16e38) .61
67 63 .55




































Figure 1. Summary of implant outcomes in the 2 groups. IPP ¼
inﬂatable penile prosthesis; MPP ¼ malleable penile prosthesis.
Malleable Implant Is an Option in PD and ED 2718% received an IPP. In the overall cohort, preoperative penile
curvatures were dorsal in 34%, lateral in 31%, ventral in 23%,
and multiplanar in 12%. The mean preoperative curvature in the
entire cohort was 65 (range ¼ 30e130; 67 in MPP group,
63 in IPP group; P ¼ .55)Implant Outcomes
Of the entire cohort, 92% had total resolution of their
curvature (0) and 8% had residual curvature (mean ¼ 32,
range ¼ 25e40) requiring adjuvant maneuvers (plaque incision
and/or excision). Implant outcomes in the 2 groups are presented
in Figure 1. At the end of surgery (placement of prosthesis with
or without extra maneuvers), curvature was completely ﬁxed in
94% of the MPP group and completely ﬁxed in 83% of the IPP
group (P ¼ .48). There was no signiﬁcant difference in
complication rate between the MPP and IPP groups. Major
complications included 4 cases with wound infection (3 withSex Med 2018;6:24e29MPP and 1 with IPP). All responded well to conservative therapy
and achieved complete healing. Minor complications included
temporary penoscrotal edema, ecchymosis, and local pain
occurred in most men.Questionnaire Outcomes
There was no statistically signiﬁcant difference between the
MPP and IPP groups in postoperative satisfaction scores or
SHIM scores (Table 2). The postoperative SHIM score was
obtained 3 months after surgery and repeated at 6, 12, and 24
months. This satisfaction rate was sustained in the 2 groups at a
mean follow-up period of 23.4 months (range ¼ 6e29 months).
DISCUSSION
PD prevalence rates of 0.4% to 9% have been published.13
PD is frequently associated with ED and a variety of other co-
morbid disorders, including diabetes, hypertension, and radical
prostatectomy. 2 thirds of patients with PD are likely to have risk
factors for arterial disease and therefore worsening long-term
erectile function.14 Usta et al15 reported that ED in men with
PD ranged from 20% to 54%.
Because PD is associated in many patients with impaired
sexual functioning, true sexual dysfunction as a result of the
penile deformity must be assessed. Inability of the patient to
engage in penetrative sexual intercourse can be related primarily
to penile deformity, which physically limits penile penetration;
pain (during sexual activity) experienced by the patient or partner
as a result of the penile deformity; or ED, by which the penis
cannot achieve or maintain the rigidity necessary for the
completion of intercourse.16
The purpose of surgery for the treatment of PD is to enable
the patient to resume satisfactory sexual activities. This requires a
functionally straight and sufﬁciently rigid penis to enable him to
accomplish penetrative intercourse. Penile implantation can
address these 2 issues simultaneously.16
Historically, the IPP has been associated with higher func-
tional satisfaction and lower persistent curvature rates. The
3-piece IPP cylinders allow more ﬂexible sizing. It is generally
recommended that cylinders that expand in length should be
avoided. The 2-piece hydraulic Ambicor IPP (AMS, Minneap-
olis, MN, USA) can be used in PD when placement of an intra-
abdominal reservoir poses a problem. However, these devices do
not deﬂate fully (because they are preﬁlled) and can be difﬁcult
to place when there is some degree of constriction within the
corpus cavernosum.7,12,17
The MPP also can be used in patients with PD, although some
investigators have argued against them.10 Also, the American
Urological Association 2015 guidelines for PD state that clinicians
should use the IPP for patients undergoing penile prosthetic sur-
gery for the treatment of PD, but this recommendation is based on
expert opinion.18 These devices (MPP) are more suitable for
patients with impaired manual dexterity and for whom placement
Table 2. Questionnaire data outcome
MPP group IPP group P value*
Preoperative SHIM score, mean ± SD (range) 9.1 ± 2.6 (6e16) 8.6 ± 2.5 (6e14) .32
Postoperative SHIM score, mean ± SD (range) 22.5 ± 2.5 (12e25) 22.3 ± 2.5 (13e25) .64
Postoperative satisfaction, mean ± SD (range) 4.4 ± 0.7 (2e5) 4.3 ± 0.8 (2e5) .32
IPP ¼ inﬂatable penile prosthesis; MPP ¼ malleable penile prosthesis; SHIM ¼ Sexual Health Inventory for Men.
*IPP vs MPP group.
28 Habous et alof an IPP would prove difﬁcult. Montorsi et al10 reported that
placement of an MPP for PD was associated with a signiﬁcant
patient-partner dissatisfaction rate. They assessed the long-term
acceptance of and satisfaction with penile implants in patients
with PD and their partners. From 1985 to 1987, 50 men with PD
and associated ED were treated with an MPP without additional
plaque surgery. 48 patients and 29 partners were reassessed at a
follow-up of at least 60 months. Only 23 patients (48%) and 12
partners (40%) were totally satisﬁed with the long-term functional
result and would repeat the same operation. For the 25 patients
(52%) dissatisﬁed with the procedure, loss of natural tumescence
resulting in a pencil-like penis, decrease in penile sensitivity, poor
concealment, and persistence of penile deviation were the major
complaints. Of the partners, 17 (60%) were dissatisﬁed because of
poor penile girth, sensation of a cold glans, sensation of unnatural
intercourse, and dyspareunia.10 How different the patient or
partner satisfaction would have been with the IPP is not known
from this study.7
In our study, 94% of our MPP group achieved a completely
straight penis at the end of the operation and this continued
through the end of the follow-up period. In the MPP group, the
mean satisfaction score 3 months postoperatively was compara-
ble to that of the IPP group. This satisfaction rate also was
durable, with a mean follow-up period of 23.4 months (6e29
months). We believe that the reason we could achieve such
excellent straightening of curvature without adjuvant maneuvers
is that during corporal dilation we have to dilate aggressively to
create a wide enough space for the MPP. We believe this to be a
critical factor in disrupting intracorporal synechiae, which might
play some role in curvature in men with PD, to straighten the
penis. Optimal outcomes with the MPP could use the modeling
procedure used for the IPP. 20% of our patients who received
the MPP required this for signiﬁcant residual curvature after
implant placement. Modeling failed to correct the residual cur-
vature in 21% and plaque incision was required for the
remainder of the patients who received the MPP. This is com-
parable to the need for this procedure in the IPP group in our
analysis.
In support of our ﬁndings, Ghanem et al19 reported their
experience in a much smaller group (20 men) with PD who
underwent placement of an MPP. They reported complete
straightening of the penile shaft in 65% of their patients, whereas
the remaining patients had some degree of deviation. They alsoreported a high rate of satisfaction (87%). They concluded the
safety and effectiveness of the MPP in the management of PD
associated with ED.
In addition to the lower cost of the MPP, the simplicity of the
procedure for the surgeon and patient is a potential signiﬁcant
advantage. Based on our data, we believe that using the MPP is a
reasonable approach for patients who have PD and ED. In
certain regions of the world where patients pay for the implant
(no insurance coverage), the MPP is an excellent choice for those
patients. There is little doubt that the cultural milieu and so-
cioeconomic factors have played some role in the acceptance of
the MPP. We believe that insurance coverage for penile implant
surgery in countries such as the United States has a major role in
the domination of the IPP, which might not be the case if it were
not covered. However, the fact is the MPP can be used to correct
penile curvature in men with PD.
To our knowledge, this is the largest published series assessing
the outcome of MPP placement in patients with PD with a
comparison of the outcome of IPP placement at the same center.
However, this was not a randomized controlled study, although
randomized controlled trials in the surgical space are notoriously
difﬁcult to conduct. Furthermore, no assessment of postoperative
penile length or long-term residual deformity was performed,
which would have added value to the study. Moreover, a ran-
domized controlled trial likely would have affected only patient
satisfaction outcomes and have little effect on data pertaining to
curvature correction with an implant. Other limitations are the
medium-term follow-up, a small number of patients receiving
the IPP, and lack of a validated instrument for satisfaction after
surgery.
Therefore, although a consensus on the ideal surgical method
for the reconstruction of penile deformity in men with ED does
not exist, current efforts should focus on reaching a consensus on
the ideal way to follow these patients in the long term and
compare the outcome in all aspects including cost.CONCLUSIONS
We have demonstrated that the ability of MPP to restore
functional erections is excellent, as good as the IPP, at least if
adjuvant intraoperative maneuvers are used when residual cur-
vature is encountered. Furthermore, there appears to be noSex Med 2018;6:24e29
Malleable Implant Is an Option in PD and ED 29difference in satisfaction between patients who received the MPP
and those who received the IPP.
Corresponding Author: Mohamad Habous, MD, FEBU,
FECSM, Consultant Urologist, Elaj Medical Centers, 2527
Qurysh Street, Box 117364, Albawady District, Jeddah 21391,
Saudi Arabia. Tel: 966-12-6063030; Fax: 966-12-6928192;
E-mail: drmhabos@hotmail.com
Conﬂicts of Interest: The authors report no conﬂicts of interest.
Funding: None.STATEMENT OF AUTHORSHIP
Category 1
(a) Conception and DesignSexMohamad Habous; Alaa Tealab; David Ralph; Saleh Binsaleh;
John Mulhall(b) Acquisition of Data
Mohamad Habous; Alaa Tealab; Mohammed Farag; Tarek
Soliman; Saad Mahmoud; Amin Elserafy; Zenhom Mekawi;
Abdallah Remeah; Mohammed Nassar; Osama Laban(c) Analysis and Interpretation of Data
Mohamad Habous; Ben Williamson; Osama Abdelwahab;
Simone Giona; John MulhallCategory 2
(a) Drafting the Article
Mohamad Habous; Alaa Tealab; Mohammed Farag; John
Mulhall(b) Revising It for Intellectual Content
Mohamad Habous; David Ralph; John MulhallCategory 3
(a) Final Approval of the Completed Article
Mohamad Habous; John MulhallREFERENCES
1. Carson CC. Penile prostheses: are they still relevant? BJU Int
2003;91:176-177.
2. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The manage-
ment of Peyronie’s disease: evidence-based 2010 guidelines.
J Sex Med 2010;7:2359-2374.
3. Levine LA, Larsen SM. Surgery for Peyronie’s disease. Asian J
Androl 2013;15:27-34.Med 2018;6:24e294. Chaudhary M, Sheikh N, Asterling S, et al. Peyronie’s disease
with erectile dysfunction: penile modeling over inﬂatable penile
prostheses. Urology 2005;65:760-764.
5. Wilson SK, Delk JR II. A new treatment for Peyronie’s disease:
modeling the penis over an inﬂatable penile prosthesis. J Urol
1994;152:1121-1123.
6. Garaffa G, Minervini A, Christopher NA, et al. The manage-
ment of residual curvature after penile prosthesis implantation
in men with Peyronie’s disease. BJU Int 2011;108:1152-1156.
7. Levine LA, Benson J, Hoover C. Inﬂatable penile prosthesis place-
ment in men with Peyronie’s disease and drug-resistant erectile
dysfunction: a single-center study. J SexMed 2010;7:3775-3783.
8. Wilson SK. Surgical techniques: modeling technique for penile
curvature. J Sex Med 2007;4:231-234.
9. Carson CC. Penile prosthesis implantation in the treatment of
Peyronie’s disease and erectile dysfunction. Int J Impot Res
2000;12:122-126.
10. Montorsi F, Guazzoni G, Bergamaschi F, et al. Patient-partner
satisfaction with semirigid penile prosthesis for Peyronie’s
disease: a 5-year follow-up study. J Urol 1993;150:1819-1821.
11. Levine LA, Becher E, Bella A, et al. Penile prosthesis surgery:
current recommendations from the International Consultation
on Sexual Medicine. J Sex Med 2016;13:489-518.
12. Mulcahy JJ, Wilson SK. Management of Peyronie’s disease
with penile prostheses. Int J Impot Res 2002;14:384-388.
13. Sommer F, Schwarzer U, Wassmer G, et al. Epidemiology of
Peyronie’s disease. Int J Impot Res 2002;14:379-383.
14. Ralph DJ. Long-term results of the surgical treatment of
Peyronie’s disease with plaque incision and grafting. Asian
J Androl 2011;13:797.
15. Usta MF, Bivalacqua TJ, Tokatli Z, et al. Stratiﬁcation of penile
vascular pathologies in patients with Peyronie’s disease and in
man with erectile dysfunction according to age: a comparative
study. J Urol 2004;172:259-262.
16. Segal RL, Burnett AL. Surgical management for Peyronie’s
disease.World J Mens Health 2013;31:1-11.
17. Kowalczyk JJ, Mulcahy JJ. Penile curvatures and aneurysmal
defects with the Ultrex penile prosthesis corrected with
insertion of the AMS 700 CX. J Urol 1996;156:398-401.
18. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease:
AUA guideline. J Urol 2015;194:745-753.
19. Ghanem HM, Fahmy I, El-Meliegy A. Malleable penile implants
without plaque surgery in the treatment of Peyronie’s disease.
Int J Impot Res 1998;10:171-173.
